Regulatory Biogen’s salanersen gains FDA breakthrough therapy designation for SMA Pharmaceutical Business ReviewThis advance recognises preliminary data indicating that salanersen may show substantial improvement over existing therapies for SMA.NeuroscienceRead full story pharminent June 5, 2026 (Last updated: June 5, 2026) Pharmaceutical Business Review This advance recognises preliminary data indicating that salanersen may show substantial improvement over existing therapies for SMA. Neuroscience Read full story Post navigation Previous: Pfizer signs licence agreement with Chai for AI drug discoveryNext: Pharma is betting big on PD-1/VEGF bispecifics. But are companies chasing the wrong target? Related Stories Regulatory Scholar Rock’s muscle-targeting SMA therapy Isemblyd lands FDA approval pharminent September 14, 2026 Regulatory Psychedelic therapies ride wave of public favor into FDA hearing pharminent September 14, 2026 Regulatory Bayer’s Hyrnuo set for the NSCLC frontlines on accelerated FDA label expansion pharminent September 10, 2026